Dr John Mandrola reviews multiple studies from the American Heart Association 2015 Scientific Sessions in this week's podcast.

A recent study serves as a reminder to ask patients with VTE about their emotional health as well as their physical well-being.

In homage to Dr Seuss, Dr Wharton adds rhyming couplets to the explanation for this echo case challenge.

Treating patients with severe asymptomatic aortic stenosis, dabigatran reversal, valve-in-valve TAVR, and an oral potassium binder are the topics for this week's podcast from Dr John Mandrola

Overall, PE is underdiagnosed, but Dr Goldhaber reviews a paper on overdiagnosis and provides suggestions on how to avoid it.

The SPRINT hypertension trial announcement, ABIM concessions, frailty as a predictor of PCI outcomes, and high interval training as therapy in type 2 diabetes are discussed in this week's podcast.

Dr Goldhaber interviews Dr Pollack about the REVERSE-AD study evaluating a new dabigatran reversal agent and what the future holds for other NOAC reversal agents.

Dr John Mandrola discusses studies from ESC, including CT-FFR, post-PCI bivalirudin, ezetimibe in diabetes, high-sensitivity troponin, resistant HTN, leadless pacing, and afternoon naps.

UPDATED with Transcript // The panel discuss a leadless pacemaker, cyclosporine and reperfusion injury, hypertension treatments, high-sensitivity troponin for early MI diagnosis, and yet more data on antithrombins for PCI.

Two underused treatments for patients with CHF, mobile health apps, a potential breakthrough in obesity, and surgical AF ablation are discussed by Dr. John Mandrola.